355 related articles for article (PubMed ID: 33342753)
1. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.
Morales DR; Conover MM; You SC; Pratt N; Kostka K; Duarte-Salles T; Fernández-Bertolín S; Aragón M; DuVall SL; Lynch K; Falconer T; van Bochove K; Sung C; Matheny ME; Lambert CG; Nyberg F; Alshammari TM; Williams AE; Park RW; Weaver J; Sena AG; Schuemie MJ; Rijnbeek PR; Williams RD; Lane JCE; Prats-Uribe A; Zhang L; Areia C; Krumholz HM; Prieto-Alhambra D; Ryan PB; Hripcsak G; Suchard MA
Lancet Digit Health; 2021 Feb; 3(2):e98-e114. PubMed ID: 33342753
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.
Morales DR; Conover MM; You SC; Pratt N; Kostka K; Duarte-Salles T; Fernández-Bertolín S; Aragón M; DuVall SL; Lynch K; Falconer T; van Bochove K; Sung C; Matheny ME; Lambert CG; Nyberg F; Alshammari TM; Williams AE; Park RW; Weaver J; Sena AG; Schuemie MJ; Rijnbeek PR; Williams RD; Lane JCE; Prats-Uribe A; Zhang L; Areia C; Krumholz HM; Prieto-Alhambra D; Ryan PB; Hripcsak G; Suchard MA
medRxiv; 2020 Jun; ():. PubMed ID: 32587982
[TBL] [Abstract][Full Text] [Related]
3. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
4. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.
Lu Y; Van Zandt M; Liu Y; Li J; Wang X; Chen Y; Chen Z; Cho J; Dorajoo SR; Feng M; Hsu MH; Hsu JC; Iqbal U; Jonnagaddala J; Li YC; Liaw ST; Lim HS; Ngiam KY; Nguyen PA; Park RW; Pratt N; Reich C; Rhee SY; Sathappan SMK; Shin SJ; Tan HX; You SC; Zhang X; Krumholz HM; Suchard MA; Xu H
JAMA Netw Open; 2022 Mar; 5(3):e223877. PubMed ID: 35323951
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy.
Wen X; Otoo MN; Tang J; Brothers T; Ward KE; Asal N; Meador KJ
JAMA Neurol; 2024 Jun; ():. PubMed ID: 38884986
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Suchard MA; Schuemie MJ; Krumholz HM; You SC; Chen R; Pratt N; Reich CG; Duke J; Madigan D; Hripcsak G; Ryan PB
Lancet; 2019 Nov; 394(10211):1816-1826. PubMed ID: 31668726
[TBL] [Abstract][Full Text] [Related]
8. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
9. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
Hsieh MS; How CK; Hsieh VC; Chen PC
Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
Choksi TT; Zhang H; Chen T; Malhotra N
Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
[TBL] [Abstract][Full Text] [Related]
12. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
14. Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study.
Choi J; Lee SR; Choi EK; Lee KY; Ahn HJ; Kwon S; Kim B; Han KD; Oh S; Lip GYH
Front Cardiovasc Med; 2024; 11():1372505. PubMed ID: 38784173
[TBL] [Abstract][Full Text] [Related]
15. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
[TBL] [Abstract][Full Text] [Related]
16. Association of Long-term Use of Antihypertensive Medications With Late Outcomes Among Patients With Aortic Dissection.
Chen SW; Chan YH; Lin CP; Wu VC; Cheng YT; Chen DY; Chang SH; Hung KC; Chu PH; Chou AH
JAMA Netw Open; 2021 Mar; 4(3):e210469. PubMed ID: 33656527
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
18. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
Graham DJ; Izurieta HS; Muthuri SG; Zhang D; Sandhu AT; Lu Y; Zhao Y; Feng Y; Eworuke E; Lyu H; Gandotra C; Smith ER; Avagyan A; Wernecke M; Kelman JA; Forshee RA; MaCurdy TE
J Gen Intern Med; 2021 Dec; 36(12):3802-3809. PubMed ID: 34599472
[TBL] [Abstract][Full Text] [Related]
19. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
Safizadeh F; Nguyen TNM; Brenner H; Schöttker B
Br J Clin Pharmacol; 2022 Jun; 88(6):2830-2842. PubMed ID: 34935181
[TBL] [Abstract][Full Text] [Related]
20. Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.
Bae S; Kim JH; Kim YJ; Lim JS; Yun SC; Kim YH; Lee SO; Kim SH
Open Forum Infect Dis; 2020 Nov; 7(11):ofaa519. PubMed ID: 33235892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
